Literature DB >> 28790031

BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer.

Shin-Heng Chiou1, Viviana I Risca1, Gordon X Wang2, Dian Yang1,3, Barbara M Grüner1, Arwa S Kathiria1, Rosanna K Ma1, Dedeepya Vaka4, Pauline Chu4, Margaret Kozak5, Laura Castellini6, Edward E Graves3,5,6, Grace E Kim7, Philippe Mourrain2, Albert C Koong3,5,6, Amato J Giaccia3,5,6, Monte M Winslow8,3,4,5.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most metastatic and deadly cancers. Despite the clinical significance of metastatic spread, our understanding of molecular mechanisms that drive PDAC metastatic ability remains limited. By generating a genetically engineered mouse model of human PDAC, we uncover a transient subpopulation of cancer cells with exceptionally high metastatic ability. Global gene expression profiling and functional analyses uncovered the transcription factor BLIMP1 as a driver of PDAC metastasis. The highly metastatic PDAC subpopulation is enriched for hypoxia-induced genes, and hypoxia-mediated induction of BLIMP1 contributes to the regulation of a subset of hypoxia-associated gene expression programs. These findings support a model in which upregulation of BLIMP1 links microenvironmental cues to a metastatic stem cell character.Significance: PDAC is an almost uniformly lethal cancer, largely due to its tendency for metastasis. We define a highly metastatic subpopulation of cancer cells, uncover a key transcriptional regulator of metastatic ability, and define hypoxia as an important factor within the tumor microenvironment that increases metastatic proclivity. Cancer Discov; 7(10); 1184-99. ©2017 AACR.See related commentary by Vakoc and Tuveson, p. 1067This article is highlighted in the In This Issue feature, p. 1047. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28790031      PMCID: PMC5628145          DOI: 10.1158/2159-8290.CD-17-0250

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  81 in total

1.  DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer.

Authors:  V Moncho-Amor; I Ibañez de Cáceres; E Bandres; B Martínez-Poveda; J L Orgaz; I Sánchez-Pérez; S Zazo; A Rovira; J Albanell; B Jiménez; F Rojo; C Belda-Iniesta; J García-Foncillas; R Perona
Journal:  Oncogene       Date:  2010-10-04       Impact factor: 9.867

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

3.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

4.  Hypoxia enhances the generation of induced pluripotent stem cells.

Authors:  Yoshinori Yoshida; Kazutoshi Takahashi; Keisuke Okita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Cell Stem Cell       Date:  2009-08-27       Impact factor: 24.633

5.  RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.

Authors:  Martin C Whittle; Kamel Izeradjene; P Geetha Rani; Libing Feng; Markus A Carlson; Kathleen E DelGiorno; Laura D Wood; Michael Goggins; Ralph H Hruban; Amy E Chang; Philamer Calses; Shelley M Thorsen; Sunil R Hingorani
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

6.  Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5.

Authors:  Mathilde Romagnoli; Karine Belguise; Ziyang Yu; Xiaobo Wang; Esther Landesman-Bollag; David C Seldin; Dany Chalbos; Sophie Barillé-Nion; Pascal Jézéquel; Margaret L Seldin; Gail E Sonenshein
Journal:  Cancer Res       Date:  2012-10-10       Impact factor: 12.701

7.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

Authors:  Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

8.  B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites.

Authors:  Tracy C Kuo; Kathryn L Calame
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

9.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

10.  Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family.

Authors:  Kazuo Motoyama; Hiroshi Inoue; Yoshito Nakamura; Hiroyuki Uetake; Kenichi Sugihara; Masaki Mori
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

View more
  23 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 2.  Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity.

Authors:  Jin Qian; Erinn B Rankin
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

4.  Five gene signatures were identified in the prediction of overall survival in resectable pancreatic cancer.

Authors:  Chao Wu; Zuowei Wu; Bole Tian
Journal:  BMC Surg       Date:  2020-09-17       Impact factor: 2.102

5.  MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma.

Authors:  Ravikanth Maddipati; Robert J Norgard; Timour Baslan; Komal S Rathi; Amy Zhang; Asal Saeid; Taku Higashihara; Feng Wu; Angad Kumar; Valli Annamalai; Saurav Bhattacharya; Pichai Raman; Christian A Adkisson; Jason R Pitarresi; Maximilian D Wengyn; Taiji Yamazoe; Jinyang Li; David Balli; Michael J LaRiviere; Tuong-Vi C Ngo; Ian W Folkert; Ian D Millstein; Jonathan Bermeo; Erica L Carpenter; John C McAuliffe; Maja H Oktay; Rolf A Brekken; Scott W Lowe; Christine A Iacobuzio-Donahue; Faiyaz Notta; Ben Z Stanger
Journal:  Cancer Discov       Date:  2021-09-22       Impact factor: 38.272

6.  Metastatic tumor cells - genotypes and phenotypes.

Authors:  Dingcheng Gao; Vivek Mittal; Yi Ban; Ana Rita Lourenco; Shira Yomtoubian; Sharrell Lee
Journal:  Front Biol (Beijing)       Date:  2018-08-20

Review 7.  The biology of pancreatic cancer morphology.

Authors:  Oliver G McDonald
Journal:  Pathology       Date:  2021-12-03       Impact factor: 5.306

Review 8.  Drivers of Gene Expression Dysregulation in Pancreatic Cancer.

Authors:  Swati Venkat; Abdulrahman A Alahmari; Michael E Feigin
Journal:  Trends Cancer       Date:  2021-02-19

9.  PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability.

Authors:  Jason R Pitarresi; Robert J Norgard; Anna M Chiarella; Kensuke Suzuki; Basil Bakir; Varun Sahu; Jinyang Li; Jun Zhao; Benoît Marchand; Maximilian D Wengyn; Antony Hsieh; Il-Kyu Kim; Amy Zhang; Karine Sellin; Vivian Lee; Shigetsugu Takano; Yoji Miyahara; Masayuki Ohtsuka; Anirban Maitra; Faiyaz Notta; Richard Kremer; Ben Z Stanger; Anil K Rustgi
Journal:  Cancer Discov       Date:  2021-02-15       Impact factor: 38.272

10.  NSD2 is a conserved driver of metastatic prostate cancer progression.

Authors:  Alvaro Aytes; Arianna Giacobbe; Antonina Mitrofanova; Katia Ruggero; Joanna Cyrta; Juan Arriaga; Luis Palomero; Sonia Farran-Matas; Mark A Rubin; Michael M Shen; Andrea Califano; Cory Abate-Shen
Journal:  Nat Commun       Date:  2018-12-05       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.